ImmunoOnc with CardioOnc - Great to meet Heather Shaw my boss from Immuno-Oncology Clinical Network with mentor Anna Olsson-Brown - at #BCOS2023 British Cardiovascular Society BCOS Royal College of Physicians International Cardio-Oncology Society The Immunobuddies Podcast Dr Arjun Ghosh (London Cardio-Oncology) Ricky Frazer Susannah Stanway

RUBY - chemotherapy +/- dostarlimab #ImmunoOnc
🙌Overall survival improved in MMRd and overall population of #EndometrialCancer
😑No data presented for MMRp alone....
#ESMO2023 #gyncsm #ImmunoOnc

That’s a wrap #SSO2024 . #UCSFSurgOnc in force with posters, presentations, & moderating. Great ImmunoOnc sessions with brilliant colleagues, and even a The Society of MSKCC reunion. UCSF Surgery UCSF Helen Diller Family Comprehensive Cancer Ctr Society of Surgical Oncology Paul Wong Michael David Alvarado Mohamed Adam Flavio G Rocha, MD, FACS, FSSO Adam Yopp

🚨Another life-saving breakthrough at #ASCO23 ! 🌟
And you know what's also life-changing? Getting up to $20 in cash rewards with the TEMU app! Don't miss out on this giveaway! 💰
bitman.space/GEzHjw

#OvarianCancer #ImmunoOnc #gyncsm

👉👉👉Honored to meet with Dr Carl June Carl June today on his visit to @mdacc !! Thanks 🙏 to Dr Carin Hagberg, MD & MD Anderson Cancer Center team #endcancer #leusm #lymsm #CARTCD19 #ImmunoOnc Nitin Jain Bill Wierda, MD, PhD

Check out this #AACR24 poster by first author, Johns Hopkins Medicine 3rd yr med student, Justin Huang. He’s thinking about how to extend benefits of immune checkpoint inhibition to pts w/ immunologically-cold tumors. 👏 👏, Justin! #OncTwitter #lcsm #RadOnc #ImmunoOnc #OncoAlert

👏Camrelizumab (anti-PD1) + famitinib (TKI) has improved response rate (42.9%) vs camrelizumab alone (22%) or chemotherapy (14.3%) in recurrent #CervicalCancer - extremely intriguing data that will need larger study
#ESMO2023 #gyncsm #ImmunoOnc

😞Combination of olaparib + cediranib + durvalumab did not improve PFS compared to chemotherapy in platinum resistant #OvarianCancer #ESMO2023 #gyncsm #ImmunoOnc

👉👉👉Prof. Nitin Jain .Nitin Jain & Prof. Naveen Pemmaraju Naveen Pemmaraju, MD spending quality time & learning from #WorldWideCARTGuru Prof. Sattva Neelapu #lymsm #leusm #MPNSM #BPDCN #ImmunoOnc #endcancer 🙌 Heme Reports

👀Neoadjuvant #ImmunoOnc in advanced MMRd #EndometrialCancer yields response rate of 37.5% and two pt w/ pathologic complete response after 2 cycles of therapy - very intriguing!
🧐Small study - n=10 - will be interesting to see further data in this space
#ESMO2023 #gyncsm

New SWOG Cancer Research Network #ICHECKIT #cancer trial S2013 asks: Can we predict which cancer patients are most at risk for serious side effects from widely used immune therapy drugs? To learn more, visit buff.ly/4270gS2 or call 1-800-4-Cancer and ask about S2013. National Cancer Institute #CRCSM #ImmunoOnc

#HemeDreamTeam meet up today gathering of the #hematology minds !! L▶️R: Prof Nitin Jain ; Dr Hima Atluri .Hima Atluri, MD ; Dr Hannah Goulart .Hannah Goulart ; Prof Pemmaraju Naveen Pemmaraju, MD 🙌 || #leusm #MPNSM #BPDCN #ImmunoOnc || #endcancer MD Anderson Cancer Center Heme Reports MPNCo&D Congress

Join us live on Friday, February 17 at 7:00 AM EST during #Tandem23 for our #CART #MedEd symposium! bit.ly/TandemCART23T #Hematology #CellTherapy #ImmunoOnc #HemOnc #MedTwitter

Carriers of CDKN2A germline melanoma predisposition have higher response rates to immunotherapy and targeted therapy compared to historical controls of sporadic melanomas -Alisa Goldstein nick #SMR23 Society Melanoma Res

#biomarkers #immunoonc

📣 #JCO #Editorial :

Neoadjuvant #Immunotherapy in #GastroesophagealCancer : A
Promising Early Signal? ➡️ brnw.ch/21wFzlx #esocsm #stcsm #immunoonc

🧐Tislelizumab (anti-PD-1) + Ociperlimab (anti-TIGIT) has promising durable activity in recurrent #CervicalCancer
🌟ORR 22% DoR 17.3 months
#ESMO2023 #gyncsm #ImmunoOnc

👉Have you seen this new Commentary?

⚙️Synthetic biology, genetic circuits and machine learning: a new age of cancer therapy

➡️buff.ly/3NeO2QF

#SyntheticBiology #GeneCircuits
#MachineLearning #Immunotherapy #ImmunoOnc

Dr Laetsch describes the role of vaccines to treat #cancer during the #CAC2Summit2023

#Immunotherapy
#ChildhoodCancer #ImmunoOnc

NEW Study of 4.2K mets from 26 tissue types to eval composition, evolution, & relevance of #microbiome . Many insights: organ-specific tropism, microbial diversity & TILs, Fusobacterium & #ImmunoOnc in #lcsm . CNS tumors stand out (Fig 2B) 👀 #btsm #AACR24
cell.com/cell/pdf/S0092…